Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB

Edward D Chan; Matthew J Strand; Michael D Iseman

doi:10.1086/597010

Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB

Clin Infect Dis. 2009 Mar 1;48(5):e50-2. doi: 10.1086/597010.

Authors

Edward D Chan¹, Matthew J Strand, Michael D Iseman

Affiliation

¹ Department of Medicine, National Jewish Health, Denver, CO 80206, USA.

PMID: 19191632
DOI: 10.1086/597010

Abstract

Multidrug-resistant tuberculosis (TB) strains resistant to the fluoroquinolones and streptomycin but susceptible to second-line injection treatment would not be defined as extensively drug-resistant TB. In a cohort of 174 patients with multidrug-resistant TB, we demonstrated that 12 patients with multidrug-resistant TB strains resistant to the fluoroquinolones and streptomycin had significantly better initial and long-term outcomes, compared with 10 patients with extensively drug-resistant TB.

Publication types

Comparative Study
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Antitubercular Agents / therapeutic use*
Cohort Studies
Extensively Drug-Resistant Tuberculosis / diagnosis
Extensively Drug-Resistant Tuberculosis / drug therapy*
Fluoroquinolones / therapeutic use*
Humans
Prognosis
Streptomycin / therapeutic use*
Treatment Outcome
Tuberculosis, Multidrug-Resistant / diagnosis
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Antitubercular Agents
Fluoroquinolones
Streptomycin